Global Oral Mucositis Market Size, Share, Forecast Report, 2020-2027

The global Oral Mucositis Market size is expected to register 7.1% CAGR during the forecast period of 2019 to 2025, with a market value of USD 2,247 million in 2018. Oral mucositis is an acute inflammation or ulceration of the oral or oropharyngeal mucosal membranes. It can cause pain/discomfort, interfere with swallowing, eating, and speech, and may lead to infection. The global oral mucositis market is driven by factors such as rising incidences of cancer globally and increasing oral mucositis drug development. For instance, according to the National Center for Biotechnology Information, oral mucositis occurs in up to 40% of cancer patients that receive chemotherapy and approaches 100% in the treatment of head and neck cancers. Additionally, according to National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the US in 2018.
Furthermore, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women. Moreover, according to WHO, there are 3.7 million cases of cancer in Europe every year. On the other hand, most of the drugs are not to be ingested, which restricts their usage for oral mucositis is projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers, and receive new patents to sustain their position in the market. For instance, in February 2019, Innovation Pharmaceuticals receives new patent for compounds for use in treatment of oral mucositis. The patent covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.

Oral Mucositis Market Segmentation

The global oral mucositis market has been segmented based on cause, end user, and region.

The market, based on cause, has been bifurcated into oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and oral mucositis caused by hematopoietic stem cell transplantation

The global market, based on end user, has been segmented into hospitals, dental clinics, oncology hospitals, and research institutes. Based on cause, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For example, according to the US Department of Health & Human Services, every year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the US. Based on end user, the hospitals segment is expected to hold a major share in the market due to its close association with cancer availability of all possible treatment options.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oral mucositis market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European oral mucositis market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The oral mucositis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oral mucositis market in the Middle East & Africa has been divided into the Middle East and Africa.

Global Oral Mucositis Market, by Cause

Oral Mucositis Caused by Chemotherapy
Oral Mucositis Caused by Radiotherapy
Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation
Global Oral Mucositis Market, by End User

Hospitals
Dental Clinics
Oncology Hospitals
Research Institutes
Key Players

The key players operating in the global oral mucositis market are Izun Pharmaceuticals Corporation, Shoreline Pharmaceuticals, Inc, AMAG Pharmaceutical Inc, Innovation Pharmaceuticals, The Himalaya Drug Company, Access pharmaceuticals, EKR therapeutics Inc, EUSA Pharma Inc, Swedish Orphan Biovitrum AB (publ), Soligenix, and Daewoong Co. Ltd.